ESC 2024 | RHEIA Trial: Transcatheter vs. Surgical Replacement in Women

The RHEIA trial is the first randomized, women-exclusive international study aimed to assess the safety and efficacy of transcatheter aortic valve implantation (TAVI) compared to surgery in symptomatic women with severe aortic stenosis. It excluded patients with bicuspid aortic valve, non-calcified valve, complex coronary artery disease, or with predictors of complications for TAVI or surgery.

El estudio incluyó a 443 pacientes, aleatorizados 1:1 para recibir TAVI con dispositivos Sapien 3/3U o cirugía con cualquier válvula disponible. El punto final primario fue la incidencia de eventos adversos a un año, incluyendo mortalidad, accidente cerebrovascular (ACV) y rehospitalización.

The study enrolled 443 patients, randomized 1:1 to receive TAVI with Sapien 3/3U devices or surgery with any available valve. The primary endpoint was the incidence of adverse events at one year, including mortality, stroke, and rehospitalization.

The average age of the participants was 73 years, and they were at low risk (STS score 2.2). Between 70-75% of the women had a small aortic annulus (<430 mm²). The primary endpoint showed an event rate of 15.6% in the surgical group versus 8.9% in the TAVI group (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.34-0.88; Log-rank p=0.03). This showed both non-inferiority and superiority for TAVI in the studied events.

Breaking down the primary endpoint, the TAVI group had lower rates of mortality, stroke, and rehospitalization in particular. In terms of safety, the TAVI group had a higher incidence of vascular complications (3.3% vs. 0.5%; p=0.007) and need for pacemaker (8.8% vs. 2.9%; p=0.001), and a lower rate of atrial fibrillation (-25.5%; p<0.001).

Read also: ESC 2024 | NOTION 3 Trial: Percutaneous Coronary Intervention in Patients with a Planned Transcatheter Aortic Valve Implantation.

The authors concluded that treatment with the SAPIEN 3 or SAPIEN 3 Ultra devices showed superiority regarding the primary endpoint, with fewer rehospitalizations and less use of inpatient resources compared to surgery.

Presented by Helene Eltchaninoff at the Hot-Line Sessions, ESC Congress 2024, August 30-September 2, London, England.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....